Inovio Pharmaceuticals Inc (INO)
9.68
-0.52
(-5.10%)
USD |
NASDAQ |
Apr 19, 16:00
9.60
-0.08
(-0.83%)
After-Hours: 20:00
Inovio Pharmaceuticals Cash from Financing (TTM): 4.995M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.995M |
| September 30, 2023 | 9.825M |
| June 30, 2023 | 12.94M |
| March 31, 2023 | 52.99M |
| December 31, 2022 | 81.84M |
| September 30, 2022 | 122.77M |
| June 30, 2022 | 118.52M |
| March 31, 2022 | 79.02M |
| December 31, 2021 | 211.50M |
| September 30, 2021 | 290.84M |
| June 30, 2021 | 289.59M |
| March 31, 2021 | 412.67M |
| December 31, 2020 | 465.28M |
| September 30, 2020 | 347.99M |
| June 30, 2020 | 365.26M |
| March 31, 2020 | 240.03M |
| December 31, 2019 | 105.40M |
| September 30, 2019 | 110.15M |
| June 30, 2019 | 109.13M |
| March 31, 2019 | 110.42M |
| December 31, 2018 | 31.04M |
| September 30, 2018 | 16.52M |
| June 30, 2018 | 72.84M |
| March 31, 2018 | 94.36M |
| December 31, 2017 | 95.69M |
| Date | Value |
|---|---|
| September 30, 2017 | 96.69M |
| June 30, 2017 | 30.17M |
| March 31, 2017 | 8.544M |
| December 31, 2016 | 7.787M |
| September 30, 2016 | 7.076M |
| June 30, 2016 | 4.434M |
| March 31, 2016 | 84.42M |
| December 31, 2015 | 84.35M |
| September 30, 2015 | 85.36M |
| June 30, 2015 | 84.13M |
| March 31, 2015 | 2.570M |
| December 31, 2014 | 72.46M |
| September 30, 2014 | 75.82M |
| June 30, 2014 | 103.92M |
| March 31, 2014 | 103.02M |
| December 31, 2013 | 52.69M |
| September 30, 2013 | 52.27M |
| June 30, 2013 | 24.89M |
| March 31, 2013 | 24.89M |
| December 31, 2012 | 5.325M |
| September 30, 2012 | 4.914M |
| June 30, 2012 | 3.688M |
| March 31, 2012 | 3.688M |
| December 31, 2011 | 28.01M |
| September 30, 2011 | 26.11M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
4.995M
Minimum
Dec 2023
465.28M
Maximum
Dec 2020
180.56M
Average
118.52M
Median
Jun 2022
Cash from Financing (TTM) Benchmarks
| Cerus Corp | 10.67M |
| Stereotaxis Inc | 0.081M |
| Viemed Healthcare Inc | 2.826M |
| AIM ImmunoTech Inc | 0.485M |
| Protalix BioTherapeutics Inc | 24.67M |